Axitinib Clinical data Trade names Inlyta AHFS/Drugs.com Monograph MedlinePlus a612017 License data EU EMA: Inlyta US FDA: Axitinib Pregnancy category AU: D US: D (Evidence of risk) Routes of administration Oral ATC code L01XE17 (WHO) Legal status Legal status AU: S4 (Prescription only) CA: ℞-only UK: POM (Prescription only) US: ℞-only Pharmacokinetic data Bioavailability 58%[1] Protein binding >99%[1] Metabolism Hepatic (mostly CYP3A4/CYP3A5-mediated but with some contributions from CYP1A2, CYP2C19, UGT1A1)[1] Biological half-life 2.5-6.1 hours[1] Excretion Faeces (41%; 12% as unchanged drug), urine (23%)[1] Identifiers IUPAC name N-Methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide CAS Number 319460-85-0 Y PubChem CID 6450551 IUPHAR/BPS 5659 ChemSpider 4953153 Y UNII C9LVQ0YUXG KEGG D03218 Y ChEBI CHEBI:66910 N ChEMBL CHEMBL1289926 N PDB ligand AXI (PDBe, RCSB PDB) ECHA InfoCard 100.166.384 Chemical and physical data Formula C22H18N4OS Molar mass 386.469 g/mol 3D model (Jmol) Interactive image SMILES O=C(NC)c4ccccc4Sc1ccc2c(c1)nnc2\C=C\c3ncccc3 InChI InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ Y Key:RITAVMQDGBJQJZ-FMIVXFBMSA-N Y NY (what is this?) (verify)